Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Current Liabilities: 2021-2024

Historic Total Current Liabilities for Autolus Therapeutics (AUTL) over the last 4 years, with Dec 2024 value amounting to $60.7 million.

  • Autolus Therapeutics' Total Current Liabilities rose 58.31% to $83.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.1 million, marking a year-over-year increase of 58.31%. This contributed to the annual value of $60.7 million for FY2024, which is 35.78% up from last year.
  • Per Autolus Therapeutics' latest filing, its Total Current Liabilities stood at $60.7 million for FY2024, which was up 35.78% from $44.7 million recorded in FY2023.
  • Autolus Therapeutics' 5-year Total Current Liabilities high stood at $60.7 million for FY2024, and its period low was $28.6 million during FY2021.
  • Over the past 3 years, Autolus Therapeutics' median Total Current Liabilities value was $46.4 million (recorded in 2022), while the average stood at $50.6 million.
  • Per our database at Business Quant, Autolus Therapeutics' Total Current Liabilities spiked by 62.40% in 2022 and then fell by 3.51% in 2023.
  • Over the past 4 years, Autolus Therapeutics' Total Current Liabilities (Yearly) stood at $28.6 million in 2021, then skyrocketed by 62.40% to $46.4 million in 2022, then declined by 3.51% to $44.7 million in 2023, then spiked by 35.78% to $60.7 million in 2024.